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ABSTRACT
Introduction: We recently reported that a
majority of opioid-dependent Malay males on
methadone therapy are cold pain sensitive. It is
postulated that common OPRM1
polymorphisms may be responsible. This study
investigated the association between 118A[G
(dbSNP rs1799971) and IVS2?691G[C (dbSNP
rs2075572) variants on cold pain responses
among opioid-dependent Malay males on
methadone maintenance therapy.
Methods: Cold pain responses including pain
threshold, pain tolerance, and pain intensity
were measured using the cold pressor test. DNA
was extracted from the venous blood before
polymerase chain reaction genotyping.
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Repeated measures analysis of variance was used
to compare the cold pain responses and OPRM1
polymorphisms (118A[G and IVS2?691G[C)
using models including genotype dominant
and recessive models, allelic additive models,
and analysis of haplotypes and diplotypes.
Results: A total of 148 participants were
recruited. With the recessive model, those
with IVS2?691 homozygous CC genotype had
a shorter cold pain tolerance time than those
without CC genotype (i.e., GG/GC genotype;
29.81 vs. 43.08 s, respectively, P = 0.048). On
the other hand, with diplotype analysis,
participants with combined homozygous 118
AA genotype and heterozygous IVS2?691 GC
genotype (i.e., AC/AG diplotype) had a longer
cold pain tolerance time than those without
this diplotype (49.34 vs. 31.48 s, respectively,
P = 0.043). Cold pain threshold was not
associated with any of the 118A[G and
IVS2?691G[C variations despite being
analyzed using various models (all P[0.05).
Conclusion: The IVS2?691 CC genotype and
AC/AG diplotype of 118A[G and
IVS2?691G[C seem to have opposing roles in
pain tolerance among opioid-dependent Malay
males on methadone therapy. Haplotypes of
OPRM1 may be associated with altered binding
affinity.
Keywords: Cold pain; Malays; Methadone
maintenance; Opioid dependence; Pain
tolerance; Polymorphism
INTRODUCTION
The opioidergic neurotransmission system is an
important processor of painful stimuli [1–4].
The l-opioid receptor (OPRM1) is a primary
target for clinically important opioid analgesics,
including methadone. Studies among healthy
subjects showed a possible role of the opioid
receptor mu 1 gene (OPRM1) in altered pain
sensitivity [5, 6]. Genetic factors that affect the
density, function, and, consequently, the
signaling efficacy of l-opioid receptors may
contribute to inter-individual variations in the
pain response to opioids [7–9].
Southeast Asia is a highly populated and
cultural-diverse region with ethnic Malays
constituting the largest population group,
mainly populating countries including
Malaysia, Indonesia, and the southern part of
the Philippines. Males who are ethnic Malays
make up the majority of opioid-dependent
patients on methadone treatment in Malaysia
[10]. We have previously reported that a
majority of opioid-dependent Malay males on
methadone therapy are cold pain sensitive and
that the pain is frequently associated with poor
sleep quality [11]. One postulated mechanism
for altered pain sensitivity in this susceptible
population is polymorphisms in the OPRM1
gene.
Some of the most frequently studied
polymorphisms of OPRM1 include 118A[G
(dbSNP rs1799971), IVS2?691G[C (dbSNP
rs2075572), and IVS2?31G[A (dbSNP
rs9479757). The association between 118A[G
polymorphism and pressure pain was first
reported by Fillingim et al. [6] and Lotsch
et al. [5], but subsequent studies failed to
replicate these preliminary reports in different
experimental pain models and in different
populations [12–14]. Similarly, the roles of
other polymorphisms on pain sensitivity,
including IVS2?691G[C and IVS2?31G[A,
have been mixed. For example, the
IVS2?691G[C polymorphism did not increase
morphine requirements in patients with pain
caused by malignant disease [7] and did not
have significant association with 24-h
post-operative opioid requirement [15]. To
summarize, available studies have raised a
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great deal of speculation over the role of OPRM1
polymorphisms in pain sensitivity and one
postulation is that this phenomenon may be
gender and ethnic dependent [16].
Recent studies indicate OPRM1
polymorphisms are associated with side effects
including changes in libido and insomnia [17],
and also methadone-related deaths [18, 19]. On
the other hand, the role of OPRM1
polymorphisms on pain sensitivity among
opioid-dependent patients on methadone is
unclear because of limited evidence. Thus far,
only one study has explored this [20] but
unfortunately the low frequencies of variants
in the study samples were a limitation. A better
understanding of OPRM1 polymorphisms in
pain and opioid response of a specific
population has implications for the treatment
of pain and addictive disease, and clinical
management of each in the presence of the
other. In the present study, we aimed to
investigate the influence of common OPRM1
polymorphisms on pain responses among




Characteristics of the sampling population have
been previously described [11]. Briefly, study
participants were opioid-dependent males
undergoing methadone treatment at Hospital
Universiti Sains Malaysia (USM) and other MMT
clinics (Kota Bharu, Pasir Mas, Pasir Puteh, and
Bachok) in the state of Kelantan, Malaysia.
Opioid dependency was defined according to
the Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition (DSM-IV) criteria [21].
They were sequentially recruited after informed
consent. Study participants were included if
they were: (a) in the national MMT program
with a duration of participation of more than
1 month; (b) more than 18 years of age; (c) free
of regular use of alcohol; (d) free of
intoxication; (e) able to understand study
protocols and to follow simple study
instructions; and (f) willing to sign written
informed consent. Exclusion criteria included
the following: (a) presence of acute medical,
surgical, or psychiatric illnesses; (b) current
intake of benzodiazepines, cannabinoids, and
barbiturates; (c) on regular anticonvulsants,
neuroleptics, or analgesics; (d) history of
chronic or ongoing acute pain; (e) history of
analgesics ingestion within 3 days before the
cold pressor test (CPT); and (f) presence of
severe cognitive impairment which might
interfere with pain assessments and/or
communication. Psychiatric illnesses were
carefully evaluated during interview of
participants, and the information verified with
their medical records and also from their
treating doctors. Participants also had to
have two consecutive negative urine
tests for morphine, tetrahydrocannabinol,
amphetamines, and benzodiazepines before
study inclusion.
This study was approved by the Human
Research Ethics Committee (HREC), Universiti
Sains Malaysia (USM) in Kelantan, Malaysia
(Reference number: USMKK/PPP/JEPeM (253.3
(14))) and the Medical Research and Ethics
Committee (MREC) at the Ministry of Health
(MOH), Malaysia (Reference number:
NMRR-13-524-16614).
Assessment of Cold Pain Threshold, Pain
Tolerance, and Pain Intensity Using
the Cold Pressor Test
The CPT method utilized in the current study
has been previously described [11]. Briefly, a
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48-quart cool box was filled with a mixture of
two-thirds crushed ice and one-third tap water.
A constant temperature of 0–2 C was
maintained by adding ice intermittently. The
non-dominant hand and forearm of participant
would be placed in the ice bath with their palm
flat at the bottom of the box, with ice water
covering the hand and approximately 10 cm of
the forearm. The test was truncated at 300 s
because the numbness associated with cold
would reduce the pain.
Pain threshold was defined as the first
experience of pain that can be identified, pain
tolerance as the time elapsed when the
participant had to withdraw his hand (i.e., the
most severe pain that a subject was willing to
tolerate), and pain intensity as the maximal
pain experienced during test on a visual analog
scale (VAS; 0–100). We examined the cold
pressor responses six times over a 24-h period
[i.e., at 0 h (at about 8.00 am), and at 2, 4, 8, 12,
and 24 h after the first test] to reduce the
diurnal variation in the cold pressor pain
response. The cold pressor pain measurements
at these six different time points were used for
subsequent data analysis.
PCR Genotyping for OPRM1
Polymorphisms
Venous blood samples (2.5 mL) were collected
in tubes containing sodium citrate and were
stored at -20 C until further processing.
Genomic DNA was extracted from the
unclotted blood using QIAamp DNA blood
mini kit (Qiagen Gmbh, Hilden, Germany)
according to the manufacturer’s instructions.
The quantity and quality of the extracted
genomic DNA was determined on the
NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Inc. Wilmington,
DE, USA) with measurements performed at
260 and 280 nm. A two-step polymerase chain
reaction (PCR) method for simultaneous OPRM1
and CYP2B6 genotyping was developed and
validated for reproducibility and specificity
through direct sequencing [22]. All PCRs were
performed in standard 0.2-mL Eppendorf PCR
tubes and carried out in a volume of 25 lL
comprising buffer [10 mM Tris–HCl (pH 8.0),
50 mM KCl, 1 mM EDTA, 0.1% Triton X-100,
50.0% glycerol (v/v)]. The reactions were
performed on the Applied Biosystems Veriti
96-well thermal cycler (Applied Biosystems,
Carlsbad, CA, USA).
Briefly, the first-step PCR (‘Set A’) was
performed using specifically designed primers
(see Table S1 in the supplementary material) to
isolate regions of interest that contain the
relevant OPRM1 polymorphisms (118A[G and
IVS2?691G[C). These were later used for the
second allele-specific PCR to avoid
amplifications of similar sequences in the
human genome that may be located outside
the gene. PCR mixture for Set A contained 1.0 U
of Biotool DNA Taq polymerase (Biotools
Biotechnological and Medical Laboratories, SA,
Madrid, Spain), 2.0 mM MgCl2, 0.2 mM dNTPs
(Biotools Biotechnological and Medical
Laboratories SA), and 0.10–0.25 lM of the
primers (Invitrogen, Waltham, MA, USA). The
cycling conditions were optimized for Set A.
Ten microlitres of the first PCR products of Set A
was analyzed using 2.0% agarose gel (Promega
Corporation, Madison, WI, USA) and 1 9 TBE
(Tris, Borate, EDTA) at 100 V for 60 min. Two
microlitres of the diluted first-step PCR products
of Set A was used as template for detection of
wild-type or mutant-type alleles in the next-step
PCR. Two secondary PCRs (Set 1 and 2) were
then carried out using identical reaction
mixtures described for the first-step PCR, with
the exceptions of primer concentrations shown
in Table S1 in the supplementary material. The
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cycling conditions were again optimized and
10 ll of the second PCR products were again
analyzed using 2.0% agarose gel and 1 9 TBE at
100 V for 60 min.
Statistical Analysis
Genotyping data were analyzed using the
population genetic data analytical program,
Golden Helix SNP and Variation Suite 7 (SVS 7,
version 7.3.1; Golden Helix Inc., Bozeman, MT,
USA) based on an expectation–maximization
(EM) algorithm for the following procedures:
(a) the calculationofOPRM1 alleles andgenotype
frequencies; (b) the estimation of heterozygosity
in each polymorphism in Hardy–Weinberg
proportion; and (c) the estimation of
maximum-likelihood haplotype frequency.
Repeated measures analysis of variance
(RM-ANOVA) was used to compare mean
differences of cold pain responses between
OPRM1 polymorphisms (118A[G and
IVS2?691G[C) according to their genotypes
and allelic additive models, genotype dominant
and recessive models, haplotypes and also
diplotypes (frequency less than 10.0% were
pooled). Statistical analysis was performed
using SPSS/Win software (version 22; SPSS, Inc.,
Chicago, IL, USA). There was no correction for
multiple testing since only one gene was tested
[23]. All confidence intervals (CIs) were
computed at the 95% level. A P value\0.05 was
considered significant.
RESULTS
Characteristics of Study Participants
From March to October 2013, 169 patients were
screened: 148 completed the study and 21 failed
the screening. Twelve patients were excluded
for health reasons, 3 for scheduling conflicts,
and 6 for miscellaneous reasons. The mean age
of the study participants was 36.86 [standard
deviation (SD) 6.13, range 25–55] years. The
majority of the participants used more than one
illicit drug in their lifetime with marijuana and
amphetamines being the most widely used. Ten
(6.8%) participants reported morphine and
related substances as their past illicit drug use.
The mean duration in the MMT program was
2.82 (SD 2.02, range 0.33–9.00) years. The mean
daily methadone dose was 72.70 (SD 28.25,
range 20–160) mg/day. There was no
correlation between daily methadone dose and
duration in the MMT program (r = 0.06,
P = 0.485).
Genotyping Frequencies of OPRM1
Polymorphisms
The 118A/G and IVS2?691G/C alleles of the
OPRM1 gene were successfully amplified from
148 subjects. Their genotype and allele
frequencies are shown in Table S2 in the
supplementary material. One participant
carried the homozygous wild-type (IVS2?691
GG) genotype of the IVS2?691G[C
polymorphism. The distributions of genotypes
for the above polymorphisms followed the
Hardy–Weinberg equilibrium (P[0.078).
Assuming a mutant allele was a high-risk
allele, genotype frequencies under dominant
and recessive model were determined for these
polymorphisms (see Table S2 in the
supplementary material). The most likely
haplotype pair (i.e., diplotype) for each
genotype in each individual was estimated and
the haplotype frequency distributions were
obtained with an expectation-maximum (EM)
algorithm haplotypes. Their estimated
haplotype and diplotype frequencies are as
shown in Table S3 in the supplementary
material. On the basis of the genotyping data
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of subjects included in the study, the
standardized linkage disequilibrium value
(Levontin’s D0) and correlation coefficient (r2)
between 118A[G and IVS2?691G[C
polymorphisms were 0.473 and 0.031,
respectively [x2 (df) = 9.176 (1), P = 0.0026].
Association Between Cold Pain Parameters
and Polymorphisms of OPRM1
Cold pain threshold was not associated with
any of the 118A[G and IVS2?691G[C
variations despite being analyzed using various
models including dominant and recessive
models, allelic additive models, as well as
haplotype and diplotypes analyses (all
P[0.05; Table 1). Likewise, none of 118A[G
and IVS2?691G[C variations were associated
with cold pain intensity despite various models
(all P[0.05; Table 2). Table 3 shows the
relationship between variants of 118A[G and
IVS2?691G[C with cold pain tolerance time.
With the recessive model, those with IVS2?691
homozygous CC genotype had a shorter cold
pain tolerance time than those without CC
genotype (GG/GC genotype; 29.81 s vs. 43.08 s,
respectively, P = 0.048). Variations in the
118A[G polymorphism were not associated
with cold pain tolerance time (all P[0.05;
Table 3). However, with diplotype analysis,
participants with combined homozygous 118
AA genotype and heterozygous IVS2?691 GC
genotype (AC/AG diplotype) had a longer cold
pain tolerance time than those without this
diplotype (49.34 s vs. 31.48 s, respectively,
P = 0.043).
DISCUSSION
The 118G allele frequency of 40.2% in our study
is in good agreement with previous smaller scale
studies of this polymorphism among Malay
drug addicts in Malaysia [24] and
heroin-dependent Malays in Singapore [25],
although ours was much higher compared to
intravenous drug users on MMT [26]. Likewise,
frequency of variant IVS2?691C allele of 83.1%
in our subjects is similar to those reports from
heroin-dependent Malays in Singapore [25].
The reported frequency in our study seems to
have contrasted with those of the Chinese
(73.1%) and Indian (75%) Singaporeans [25],
as well as the Chinese (69.3%) in Hong Kong
[27]. The above reports indicate that variability
in frequency of 118G and IVS2?691C allele in
populations on methadone treatment may be
an ethnic-dependent phenomena.
In the current study, there was no
association seen between 118A[G variations
with cold pain threshold and pain tolerance.
Instead, IVS2?691G[C polymorphisms using
different models were shown to affect cold pain
tolerance, but not pain threshold and pain
intensity. These include homozygous CC
genotype (a significant shorter pain tolerance
time in CC vs. GG/GC) and combined
homozygous 118 AA genotype and
heterozygous IVS2?691 GC genotype (AC/AG
diplotype; a significant longer pain tolerance
time with this diplotype vs. without this
diplotype). We have previously reported that a
majority of opioid-dependent Malay males on
methadone therapy are cold pain sensitive [11]
and OPRM1 polymorphisms might be
responsible for this altered sensitivity based
upon our study results. What are the
implications of this? Any inter-individual
variations in opioid-induced hyperalgesia
among methadone users may weaken or
strengthen their determination to abstain [28],
and the knowledge of OPRM1 polymorphisms
in such a circumstance may help to provide a
prediction. In addition, this knowledge on
OPRM1 polymorphisms may help to guide the
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Table 1 Relationship between 118A[G and IVS2?691G[C polymorphisms and pain threshold in opioid-dependent
patients
Polymorphism N Meana 95% CI F statistic (df)b P valuec
Lower limit Upper limit
118A[G
Genotype (N = 146)
AA 53 24.06 16.43 31.70 0.24 (2) 0.785
AG 69 27.33 20.64 34.02
GG 24 24.11 12.76 35.46
Allele (N = 292)
A 175 25.35 21.19 29.51 0.04 (1) 0.844
G 117 26.01 20.92 31.10
Dominant model
AA 53 24.06 16.45 31.68 0.25 (1) 0.615
AG ? GG 93 26.50 20.75 32.25
Recessive model
AA ? AG 122 25.91 20.89 30.93 0.08 (1) 0.774
GG 24 24.11 12.79 35.43
IVS2?691G[C
Genotype (N = 146)
GG 1 20.41 -35.01 75.82 0.68 (2) 0.510
GC 47 29.51 21.43 37.60
CC 98 23.80 18.20 29.40
Allele (N = 292)
G 49 29.14 21.29 36.99 0.94 (1) 0.333
C 243 24.90 21.38 28.43
Dominant model
GG 1 20.41 -35.07 75.88 0.03 (1) 0.853
GC ? CC 145 25.65 21.04 30.26
Recessive model
GG ? GC 48 29.32 21.35 37.30 1.26 (1) 0.264
CC 98 23.80 18.22 29.38
Haplotype (N = 292)d
AC 131 24.04 19.22 28.86 0.40 (3) 0.751
GC 112 25.91 20.70 31.12
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Table 1 continued
Polymorphism N Meana 95% CI F statistic (df)b P valuec
Lower limit Upper limit
AG 44 29.26 20.94 37.57
GG 5 28.12 3.46 52.78
AC 131 24.04 19.23 28.85 0.60 (2) 0.547
GC 112 25.91 20.71 31.11
Combined AG and GG 49 29.14 21.28 37.00
AC 131 24.04 19.24 28.84 0.75 (1) 0.386
Not AC 161 26.90 22.56 31.23
GC 112 25.91 20.71 31.12 0.02 (1) 0.886
Not GC 180 25.43 21.32 29.53
AG 44 29.26 20.97 37.54 0.88 (1) 0.349
Not AG 248 24.97 21.48 28.46
Diplotype (N = 146)
AC/GC 47 24.88 16.73 33.03 0.41 (5) 0.839
AC/AC 31 22.72 12.68 32.75
AC/AG 22 25.96 14.05 37.87
GC/AG 21 33.13 20.94 45.32
GC/GC 20 22.92 10.43 35.42
Otherse 5 28.12 3.13 53.11
AC/GC 47 24.88 16.79 32.97 0.05 (1) 0.828
Not AC/GC 99 25.96 20.39 31.54
AC/AC 31 22.72 12.77 32.67 0.42 (1) 0.518
Not AC/AC 115 26.39 21.23 31.56
AC/AG 22 25.96 14.13 37.79 0.00 (1) 0.950
Not AC/AG 124 25.55 20.57 30.54
GC/AG 21 33.13 21.10 45.16 1.78 (1) 0.184
Not GC/AG 125 24.35 19.42 29.28
GC/GC 20 22.92 10.52 35.32 0.21 (1) 0.645
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methadone dosages and, therefore, avoid
adverse drug reactions.
Studies by Wang et al. [17] indicated that
IVS2?691G[C polymorphisms might affect the
side effects of methadone including change in
libido and insomnia. Our study suggests that
variations in IVS2?691G[C might also affect
pain tolerance. The actual functions of
IVS2?691G[C are still under investigations
but available data support its role in affinity of
transcriptional regulatory factors for the
intronic DNA sequence [29–31]. The DNA
intronic sequence could involve in alternative
DNA splicing and this results in creations of
different isoforms of human OPRM1 gene [30,
32]. It may also directly alter mRNA levels and,
therefore, affect expression of OPRM1 gene
[29–31]. Based on our results, we hypothesized
the increased expression of IVS2?691 CC
variant resulted in a higher OPRM1 availability
and because of chronic sensitization by
prolonged opioid use, it may then facilitate
opioid tolerance, hyperalgesia and subsequently
lower the pain tolerance. However, tolerance
normally indicates a rightward shift in a
dose–response curve. Since participants have
been treated with methadone anywhere from
0.3 to 9 years, sensitization may, therefore, also
be quite variable or absent. It is possible that
those participants in the program with a shorter
stay were different than those with longer
treatment times.
On the other hand, the AC/AG diplotype of
118 and IVS2?691 was associated with a longer
cold pain tolerance time. Opioid-related adverse
effects such as hyperalgesia were probably less
likely to occur in patients with AC/AG
diplotype at 118 and IVS2?691 given that the
mechanisms of opioid-induced adverse events
involve OPRM1. Thus, although 118A[G
polymorphism alone does not influence cold
pain tolerance, the 118 variant may play an
indirect role in pain modulation. A strong
linkage disequilibrium (LD) between studied
polymorphisms and unstudied polymorphisms
has been shown to exist [15, 33], and resulted in
altered binding affinity between endogenous
(and/or exogenous) opioids and OPRM1. As a
consequence, there was less hyperalgesia and,
therefore, an increase in cold pain tolerance.
There were associations, although not
significant, where variants of 118G allele and
GC haplotype of 118 and IVS2?691 caused a
higher cold pain intensity, but 118 AA genotype
resulted in a lower cold pain intensity. At this
juncture, it is difficult to explain the differential
effects on pain intensity with these
polymorphisms and further studies with larger
samples are needed. Besides individual
polymorphisms, haplotype and diplotype
Table 1 continued
Polymorphism N Meana 95% CI F statistic (df)b P valuec
Lower limit Upper limit
Not GC/GC 126 26.04 21.10 30.98
ANOVA analysis of variance, CI conﬁdence interval, N number of subject/allele/haplotype/diplotype
a Mean for pain threshold (seconds)
b Repeated measured ANOVA between group analysis was applied
c P value is signiﬁcant at\0.05
d Haplotype patterns were constructed from the two polymorphisms of OPRM1 (118A[G and IVS2?691G[C)
e Diplotype with frequency less than 10.0% was pooled under ‘others’ (included AG/GG and GC/GG)
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Table 2 Relationship between 118A[G and IVS2?691G[C polymorphisms and pain-intensity scores in
opioid-dependent patients
Polymorphism N Meana 95% CI F statistic (df)b P valuec
Lower limit Upper limit
118A[G
Genotype (N = 146)
AA 53 62.23 58.21 66.25 1.94 (2) 0.147
AG 69 66.97 63.45 70.49
GG 24 67.88 61.91 73.85
Allele (N = 292)
A 175 64.10 61.90 66.30 3.37 (1) 0.067
G 117 67.34 64.65 70.04
Dominant model
AA 53 62.23 58.23 66.23 3.84 (1) 0.052
AG ? GG 93 67.21 64.18 70.23
Recessive model
AA ? AG 122 64.91 62.24 67.58 0.80 (1) 0.373
GG 24 67.88 61.87 73.89
IVS2?691G[C
Genotype (N = 146)
GG 1 73.33 43.88 102.79 0.92 (2) 0.401
GC 47 63.12 58.82 67.41
CC 98 66.41 63.44 69.39
Allele (N = 292)
G 49 63.53 59.35 67.71 0.93 (1) 0.336
C 243 65.78 63.90 67.65
Dominant model
GG 1 73.33 43.83 102.84 0.28 (1) 0.595
GC ? CC 145 65.34 62.89 67.80
Recessive model
GG ? GC 48 63.33 59.09 67.57 1.38 (1) 0.241
CC 98 66.41 63.44 69.38
Haplotype (N = 292)d
AC 131 64.39 61.84 66.94 1.19 (3) 0.312
GC 112 67.40 64.64 70.16
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Table 2 continued
Polymorphism N Meana 95% CI F statistic (df)b P valuec
Lower limit Upper limit
AG 44 63.23 58.83 67.64
GG 5 66.17 53.09 79.24
AC 131 64.39 61.84 66.94 1.71 (2) 0.183
GC 112 67.40 64.64 70.16
Combined AG and GG 49 63.53 59.36 67.70
AC 131 64.39 61.83 66.95 1.10 (1) 0.296
Not AC 161 66.22 63.92 68.53
GC 112 67.40 64.64 70.15 3.31 (1) 0.070
Not GC 180 64.16 61.98 66.33
AG 44 63.23 58.82 67.65 1.10 (1) 0.295
Not AG 248 65.78 63.93 67.64
Diplotype (N = 146)
AC/GC 47 68.09 63.79 72.38 1.01 (5) 0.417
AC/AC 31 62.47 57.19 67.76
AC/AG 22 61.89 55.61 68.16
GC/AG 21 64.17 57.74 70.59
GC/GC 20 68.58 62.00 75.17
Otherse 5 66.17 53.00 79.33
AC/GC 47 68.09 63.81 72.36 2.28 (1) 0.133
Not AC/GC 99 64.12 61.18 67.07
AC/AC 31 62.47 57.20 67.75 1.53 (1) 0.219
Not AC/AC 115 66.19 63.45 68.93
AC/AG 22 61.89 55.62 68.15 1.45 (1) 0.231
Not AC/AG 124 66.02 63.38 68.66
GC/AG 21 64.17 57.73 70.61 0.17 (1) 0.683
Not GC/AG 125 65.61 62.97 68.25
GC/GC 20 68.58 62.00 75.16 1.06 (1) 0.305
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analyses are also necessary to clarify the
influence of OPRM1 on inter-individual
variations in pain sensitivity among
opioid-dependent patients on methadone
therapy. There is also the possibility that
heightened pain sensitivity is a result of the
prolonged opioid use itself or opioid-induced
hyperalgesia. The heightened pain sensitivity is
a form of latent hyperalgesia to chronic opioid
misuse, and subsequent methadone therapy
does not exacerbate hyperalgesia but does not
make it worse either [34, 35].
Some limitations to this study need to be
highlighted. There are a number of OPRM1
polymorphisms (such as rs1074287, rs6912029,
rs12209447, rs510769, rs3798676, rs7748401,
rs495491, rs10457090, rs589046, rs3778152,
and rs563649) but we only studied two
common variants. Only Malay males were
included but we aimed to reduce the
confounding effects of gender and ethnicity
on cold pain response [36–44]. Furthermore,
Malay males are the majority of
opioid-dependent patients on methadone
treatment in Malaysia. There were other
confounding factors such as induction of
tolerance to methadone effects, methadone
clearance and genetic variations of other
pain-related genes and genes related to
pharmacokinetics and pharmacodynamics of
methadone, which may be important. Only a
tonic pain model using cold pain was studied
here and phasic pain may differ qualitatively,
neurologically, and functionally from tonic
pain stimuli [45]. However, CPT has been
shown to be the better pain-induction
technique for methadone studies [20, 46, 47].
Lastly, our analyses did not correct for multiple
testing because of single gene being studied.
There was a significant LD between loci and it
was 47.3% of the theoretical maximum but
there was a weak correlation between single
nucleotide polymorphisms [D0 = 0.473,
r2 = 0.031, x2 (df) = 9.176 (1), P = 0.0026]. In
the view that correction was not performed for
multiple tests, these two findings would be
considered nominally significant. It is possible
that our result might be a false-positive
association partly because of limitation in
sample size. Therefore, our study may be
considered explorative in nature and it would
require replication by other investigators.
Nevertheless, our results can be considered as
a basis for further larger scale study.
CONCLUSIONS
In summary, our study indicates that the
IVS2?691 CC genotype was associated with a
shorter cold pain tolerance time but AC/AG
Table 2 continued
Polymorphism N Meana 95% CI F statistic (df)b P valuec
Lower limit Upper limit
Not GC/GC 126 64.89 62.27 67.52
ANOVA analysis of variance, CI conﬁdence interval, N number of subject/allele/haplotype/diplotype
a Mean for pain threshold (seconds)
b Repeated measured ANOVA between group analysis was applied
c P value is signiﬁcant at\0.05
d Haplotype patterns were constructed from the two polymorphisms of OPRM1 (118A[G and IVS2?691G[C)
e Diplotype with frequency less than 10.0% was pooled under ‘others’ (included AG/GG and GC/GG)
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Table 3 Relationship between 118A[G and IVS2?691G[C polymorphisms and pain tolerance in opioid-dependent
patients
Polymorphism N Meana 95% CI F statistic (df)b P valuec
Lower limit Upper limit
118A[G
Genotype (N = 146)
AA 53 36.92 26.48 47.36 0.22 (2) 0.806
AG 69 32.40 23.26 41.55
GG 24 33.19 17.68 48.69
Allele (N = 292)
A 175 35.14 29.45 40.82 0.28 (1) 0.597
G 117 32.72 25.77 39.68
Dominant model
AA 53 36.92 26.52 47.32 0.43 (1) 0.514
AG ? GG 93 32.60 24.75 40.45
Recessive model
AA ? AG 122 34.36 27.50 41.23 0.02 (1) 0.891
GG 24 33.19 17.71 48.66
IVS2?691G[C
Genotype (N = 146)
GG 1 25.07 -49.93 100.07 2.09 (2) 0.128
GC 47 43.46 32.52 54.40
CC 98 29.81 22.23 37.39
Allele (N = 292)
G 49 42.71 32.02 53.40 2.97 (1) 0.086
C 243 32.45 27.65 37.25
Dominant model
GG 1 25.07 -50.73 100.87 0.06 (1) 0.812
GC ? CC 145 34.23 27.94 40.53
Recessive model
GG ? GC 48 43.08 32.28 53.87 3.96 (1) 0.048
CC 98 29.81 22.25 37.36
Haplotyped (N = 292)
AC 131 32.38 25.82 38.94 1.02 (3) 0.382
GC 112 32.53 25.43 39.63
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Table 3 continued
Polymorphism N Meana 95% CI F statistic (df)b P valuec
Lower limit Upper limit
AG 44 43.35 32.03 54.68
GG 5 37.04 3.46 70.63
AC 131 32.38 25.83 38.93 1.48 (2) 0.229
GC 112 32.53 25.45 39.62
Combined AG and GG 49 42.71 32.00 53.42
AC 131 32.38 25.81 38.95 0.52 (1) 0.470
Not AC 161 35.63 29.70 41.55
GC 112 32.53 25.43 39.64 0.33 (1) 0.563
Not GC 180 35.19 29.59 40.80
AG 44 43.35 32.07 54.64 3.02 (1) 0.083
Not AG 248 32.54 27.79 37.29
Diplotype (N = 146)
AC/GC 47 30.08 19.06 41.10 1.02 (5) 0.409
AC/AC 31 28.10 14.53 41.67
AC/AG 22 49.34 33.24 65.45
GC/AG 21 37.95 21.47 54.44
GC/GC 20 31.82 14.92 48.71
Otherse 5 37.04 3.26 70.83
AC/GC 47 30.08 19.05 41.11 0.79 (1) 0.375
Not AC/GC 99 36.11 28.51 43.71
AC/AC 31 28.10 14.53 41.68 0.99 (1) 0.321
Not AC/AC 115 35.81 28.76 42.85
AC/AG 22 49.34 33.41 65.28 4.17 (1) 0.043
Not AC/AG 124 31.48 24.77 38.19
GC/AG 21 37.95 21.42 54.48 0.24 (1) 0.626
Not GC/AG 125 33.54 26.76 40.31
GC/GC 20 31.82 14.87 48.77 0.09 (1) 0.768
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diplotype of 118A[G and IVS2?691G[C was
associated with a longer cold pain tolerance
time in opioid-dependent Malay males on
methadone therapy. It can be postulated that
haplotypes of OPRM1 may be associated with
altered binding affinity. The OPRM1
polymorphisms may serve as an important
variable for developing directed interventions
and to guide management of pain among
opioid-dependent patients on MMT with
genetic risk for suffering pain. Personalized
medicine based on pharmacogenetics may be
able to maximize the benefits of methadone
pharmacotherapy and minimize their harms.
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